Related Experiment Video
Updated: Jan 9, 2026
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Clinical phenotypes and therapeutic outcomes in enteropathic arthritis: a multivariate analysis from a retrospective
Nicoletta Luciano1, Bernardo D'Onofrio2, Enrico Brunetta2
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele; and Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Objectives:
Enteropathic arthritis (SpA-IBD) refers to the coexistence of spondyloarthritis (SpA) and inflammatory bowel diseases (IBD). Whether the initial disease manifestation (SpA-first vs. IBD-first) influences clinical phenotypes and treatment outcomes remains uncertain. This study aimed to evaluate potential associations between disease onset and specific musculoskeletal manifestations, as well as to identify predictors of therapeutic multi-failure.
Methods:
We conducted a retrospective analysis of patients with SpA-IBD evaluated by both rheumatologists and gastroenterologists at our multidisciplinary ImmunoCenter from March 2022 to March 2024. We compared demographic, clinical, laboratory, and therapeutic characteristics of patients with SpA-first vs. IBD-first presentation. Multivariate logistic regression models were employed to assess associations between disease onset and clinical manifestations, and to identify predictors of therapeutic multi-failure.
Results:
Sixty-six patients were included (IBD-first: n=47, 71%; SpA-first: n=19, 29%). Enthesitis was more prevalent in the IBD-first group both at SpA onset (38% vs. 10%, p=0.021) and during follow-up (53% vs. 25%, p=0.034). No significant differences were observed in the frequency of axial (65% vs. 64%) and peripheral (60% vs. 66%) involvement or in laboratory parameters between the two groups. In the multivariate logistic regression, IBD-first presentation was significantly associated with a higher likelihood of developing enthesitis after adjusting for confounders (OR=0.267, 95% CI=0.076-0.942, p=0.040). Regarding treatment outcomes, psoriasis was significantly associated with increased risk of therapeutic multi-failure (OR=6.39, 95% CI=1.60-25.47, p=0.009), whereas other phenotypic features were not significantly predictive.
Conclusions:
The significantly higher likelihood of developing enthesitis in IBD-first suggests that distinct disease onset patterns and clinical phenotypes may influence musculoskeletal manifestations and treatment responses in enteropathic arthritis.
More Related Videos
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...